Improved therapeutic index (increased efficacy & reduced toxicity) by:
Passive targeted accumulation in diseased tissue
Sparing healthy tissues / organs
Protect API allowing controlled/sustained release at target
Biocompatible, biodegradable, non immunogenic
Scientifically well accepted nano delivery system
FDA is increasingly accustomed to Liposomal drugs – growth in the submissions of drug products containing nanomaterials, largest class of products being Liposomal formulations intended for cancer treatments*
Provides high entrance barriers for competition
Liposomal nano technology is advantageous in many indications (e.g. cancer, inflammation, infection)
Ayana has core competence in development & manufacturing of complex Liposomal nano-drugs
* Nature Nanotechnology Analysis (published on-line April 17, 2017)